Medical Oncology

, Volume 21, Issue 2, pp 205–206 | Cite as

Rituximab-induced tumor progression

Does it really happen?
  • Mustafa Ozguroglu
  • Hande Turna


Chronic Lymphocytic Leukemia Hairy Cell Leukaemia Medical Oncology Volume Accelerate Progression Rituxan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29(1 Suppl 2):105–112.PubMedCrossRefGoogle Scholar
  2. 2.
    Czuczman MS, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29(1 Suppl 2):36–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Al-Salman J, Salib H, Boonswang P. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. Med Oncol 2001;18(4):277–283.PubMedCrossRefGoogle Scholar
  4. 4.
    Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115(3):609–611.PubMedCrossRefGoogle Scholar
  5. 5.
    Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002;69(3):232–233.PubMedCrossRefGoogle Scholar
  6. 6.
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116(2):465–467.PubMedGoogle Scholar
  7. 7.
    Zaja F, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87(2):189–195.PubMedGoogle Scholar
  8. 8.
    Treon SP, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25(1):72–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl Med J Med 2002;346:235–242.CrossRefGoogle Scholar
  10. 10.
    Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002;29(1 Suppl 2):30–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Korte W, Jost C, Cogliatti S, Hess U, Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol 1999;10(10):1249–1250.PubMedCrossRefGoogle Scholar
  12. 12.
    Bellosillo B, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98(9):2771–2777.PubMedCrossRefGoogle Scholar
  13. 13.
    van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807–811.PubMedCrossRefGoogle Scholar
  14. 14.
    Cardarelli PM, et al. Binding to CD20 by Anti-B1 Antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51(1):15–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl 2):2–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Chow KU, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87(1):33–43.PubMedGoogle Scholar
  17. 17.
    Bienvenu J, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2(6):378–384.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  • Mustafa Ozguroglu
    • 1
  • Hande Turna
    • 1
  1. 1.Cerrahpasa Medical Faculty, Department of Internal Medicine, Section of Medical Oncology, CerrahpasaIstanbul UniversityIstanbulTurkey

Personalised recommendations